ArticleFrontiers in medicine2026
NoSAS score and the 5-year risk of incident cerebrovascular disease: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Obstructive sleep apnea (OSA) is a common but often underdiagnosed disorder linked to various adverse health outcomes, especially cerebrovascular events. This study aims to evaluate the utility of the NoSAS score in screening for high risk of cerebrovascular disease, facilitating early identification and improving clinical management of OSA in susceptible populations. Methods: This retrospective study enrolled patients from two sleep centers who underwent sleep apnea monitoring between September 2016 and December 2019. Individuals with pre-existing cerebrovascular disease were excluded from the study. Follow-up data on 5-year incident cerebrovascular events were collected via medical records or telephone interviews. Cerebrovascular events were primarily identified based on patient self-report and available clinical documentation; systematic neuroimaging confirmation was not routinely available. Participants were categorized by NoSAS score into high-risk (≥8) and low-risk (<8) groups. Logistic regression was used to assess the association between NoSAS risk classification and cerebrovascular disease incidence, and Nelson-Aalen were used to compare compared cumulative risk between groups over the 5-year period. Results: A total of 1,348 participants with complete NoSAS score data who completed follow-up were included in the analysis. Among the 690 participants in the high-risk group, the 5-year incidence of cerebrovascular disease was 9.71%. In the adjusted model, the NoSAS high-risk group had a 1.8-fold increased risk of cerebrovascular disease compared to the low-risk group (OR: 1.85, 95% CI: 1.01∼3.38; Conclusion: The NoSAS high-risk group showed a higher incidence of cerebrovascular disease, which could be used as an independent predictor of the disease and may have higher predictive value in the high-risk group of non-sleepy OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.